# AGNT, Inc.: financial statements, quarterly

AGNT · Nasdaq · CIK 1495932 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/agnt.md) · [Financials](/companies/agnt/financials.md) · [Filings](/companies/agnt/filings.md) · [Insiders](/companies/agnt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/agnt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,213](/filings/0001558370-24-014851.md) | [981 d](/filings/0001104659-26-019145.md) | [943](/filings/0001558370-25-006494.md) | [1,295](/filings/0001558370-25-009885.md) | [1,231](/filings/0001104659-25-107719.md) | [1,098 d](/filings/0001104659-26-019145.md) | [955](/filings/0001104659-26-058213.md) | [1,309](/filings/0001104659-26-090337.md) | [1,317](/filings/0001104659-25-107719.md) | [1,192 d](/filings/0001104659-26-019145.md) | [1,006](/filings/0001104659-26-058213.md) | [1,450](/filings/0001104659-26-090337.md) |
| Cost of revenue | $m | [0.8](/filings/0001558370-24-014851.md) | not reported | not reported | [0.9](/filings/0001558370-24-010473.md) | [0.9](/filings/0001558370-24-014851.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | [76.1](/filings/0001104659-26-058213.md) | [92.7](/filings/0001104659-26-090337.md) | not reported | not reported | [75.3](/filings/0001104659-26-058213.md) | [98.8](/filings/0001104659-26-090337.md) |
| Research and development | $m | [15.5](/filings/0001558370-24-014851.md) | [15.1 d](/filings/0001104659-26-019145.md) | [14.8](/filings/0001558370-25-006494.md) | [14.8](/filings/0001558370-25-009885.md) | [13.8](/filings/0001104659-25-107719.md) | [14.8 d](/filings/0001104659-26-019145.md) | [16.8](/filings/0001104659-26-058213.md) | [18.1](/filings/0001104659-26-090337.md) | [17.3](/filings/0001104659-25-107719.md) | [17.4 d](/filings/0001104659-26-019145.md) | [17.6](/filings/0001104659-26-058213.md) | [18.4](/filings/0001104659-26-090337.md) |
| Operating income | $m | [3.7](/filings/0001558370-24-014851.md) | [(16.0) d](/filings/0001104659-26-019145.md) | [(18.2)](/filings/0001558370-25-006494.md) | [18.5](/filings/0001558370-25-009885.md) | [(8.3)](/filings/0001104659-25-107719.md) | [(11.0) d](/filings/0001104659-26-019145.md) | [(10.4)](/filings/0001104659-26-058213.md) | [(2.4)](/filings/0001104659-26-090337.md) | [4.0](/filings/0001104659-25-107719.md) | [(12.7) d](/filings/0001104659-26-019145.md) | [(8.8)](/filings/0001104659-26-058213.md) | [1.6](/filings/0001104659-26-090337.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.8](/filings/0001558370-24-014851.md) | [(3.0) d](/filings/0001104659-26-019145.md) | [(3.3)](/filings/0001558370-25-006494.md) | [8.1](/filings/0001558370-25-009885.md) | [(1.3)](/filings/0001104659-25-107719.md) | [(2.4) d](/filings/0001104659-26-019145.md) | [1.7](/filings/0001104659-26-058213.md) | [0.5](/filings/0001104659-26-090337.md) | [0.9](/filings/0001104659-25-107719.md) | [(0.6) d](/filings/0001104659-26-019145.md) | [(3.6)](/filings/0001104659-26-058213.md) | [5.0](/filings/0001104659-26-090337.md) |
| Net income | $m | [1.3](/filings/0001558370-23-017439.md) | [(21.2) d](/filings/0001104659-26-019145.md) | [(15.6)](/filings/0001558370-25-006494.md) | [12.4](/filings/0001558370-25-009885.md) | [(8.5)](/filings/0001104659-25-107719.md) | [(9.5) d](/filings/0001104659-26-019145.md) | [(11.0)](/filings/0001104659-26-058213.md) | [(2.3)](/filings/0001104659-26-090337.md) | [3.5](/filings/0001104659-25-107719.md) | [(12.9) d](/filings/0001104659-26-019145.md) | [(5.1)](/filings/0001104659-26-058213.md) | [(2.7)](/filings/0001104659-26-090337.md) |
| Diluted EPS | $ per share | [0.01](/filings/0001558370-24-014851.md) | not reported | [(0.10)](/filings/0001558370-25-006494.md) | [0.08](/filings/0001558370-25-009885.md) | [(0.06)](/filings/0001104659-25-107719.md) | not reported | [(0.07)](/filings/0001104659-26-058213.md) | [(0.01)](/filings/0001104659-26-090337.md) | [0.02](/filings/0001104659-25-107719.md) | not reported | [(0.03)](/filings/0001104659-26-058213.md) | [(0.02)](/filings/0001104659-26-090337.md) |
| Basic EPS | $ per share | [0.01](/filings/0001558370-24-014851.md) | not reported | [(0.10)](/filings/0001558370-25-006494.md) | [0.08](/filings/0001558370-25-009885.md) | [(0.06)](/filings/0001104659-25-107719.md) | not reported | [(0.07)](/filings/0001104659-26-058213.md) | [(0.01)](/filings/0001104659-26-090337.md) | [0.02](/filings/0001104659-25-107719.md) | not reported | [(0.03)](/filings/0001104659-26-058213.md) | [(0.02)](/filings/0001104659-26-090337.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [120](/filings/0001558370-24-014851.md) | [126](/filings/0001558370-25-001223.md) | [109](/filings/0001558370-25-006494.md) | [108](/filings/0001558370-25-009885.md) | [130](/filings/0001104659-25-107719.md) | [114](/filings/0001104659-26-019145.md) | [116](/filings/0001104659-26-058213.md) | [94.6](/filings/0001104659-26-090337.md) | [113](/filings/0001104659-25-107719.md) | [124](/filings/0001104659-26-090337.md) | [122](/filings/0001104659-26-058213.md) | [111](/filings/0001104659-26-090337.md) |
| Current assets | $m | [300](/filings/0001558370-23-017439.md) | [266](/filings/0001558370-25-001223.md) | [300](/filings/0001558370-24-006375.md) | [336](/filings/0001558370-24-010473.md) | [310](/filings/0001558370-24-014851.md) | [268](/filings/0001104659-26-019145.md) | [301](/filings/0001558370-25-006494.md) | [345](/filings/0001558370-25-009885.md) | [323](/filings/0001104659-25-107719.md) | [305](/filings/0001104659-26-090337.md) | [329](/filings/0001104659-26-058213.md) | [391](/filings/0001104659-26-090337.md) |
| Total assets | $m | [423](/filings/0001558370-23-017439.md) | [386](/filings/0001558370-25-001223.md) | [427](/filings/0001558370-24-006375.md) | [457](/filings/0001558370-24-010473.md) | [433](/filings/0001558370-24-014851.md) | [391](/filings/0001104659-26-019145.md) | [436](/filings/0001558370-25-006494.md) | [481](/filings/0001558370-25-009885.md) | [459](/filings/0001104659-25-107719.md) | [442](/filings/0001104659-26-090337.md) | [467](/filings/0001104659-26-058213.md) | [539](/filings/0001104659-26-090337.md) |
| Current liabilities | $m | [172](/filings/0001558370-23-017439.md) | [142](/filings/0001558370-25-001223.md) | [204](/filings/0001558370-24-006375.md) | [237](/filings/0001558370-24-010473.md) | [222](/filings/0001558370-24-014851.md) | [186](/filings/0001104659-26-019145.md) | [224](/filings/0001558370-25-006494.md) | [263](/filings/0001558370-25-009885.md) | [223](/filings/0001104659-25-107719.md) | [200](/filings/0001104659-26-090337.md) | [211](/filings/0001104659-26-058213.md) | [258](/filings/0001104659-26-090337.md) |
| Total liabilities | $m | [172](/filings/0001558370-23-017439.md) | [142](/filings/0001558370-25-001223.md) | [204](/filings/0001558370-24-006375.md) | [237](/filings/0001558370-24-010473.md) | [222](/filings/0001558370-24-014851.md) | [186](/filings/0001104659-26-019145.md) | [224](/filings/0001558370-25-006494.md) | [263](/filings/0001558370-25-009885.md) | [223](/filings/0001104659-25-107719.md) | [200](/filings/0001104659-26-090337.md) | [211](/filings/0001104659-26-058213.md) | [258](/filings/0001104659-26-090337.md) |
| Long-term debt | $m | [0.0](/filings/0001558370-23-017439.md) | [0.0](/filings/0001558370-24-014851.md) | [0.0](/filings/0001558370-24-006375.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [250](/filings/0001558370-23-017439.md) | [243](/filings/0001558370-25-001223.md) | [222](/filings/0001558370-24-006375.md) | [220](/filings/0001558370-24-010473.md) | [211](/filings/0001558370-24-014851.md) | [205](/filings/0001104659-26-019145.md) | [212](/filings/0001104659-26-058213.md) | [218](/filings/0001104659-26-090337.md) | [235](/filings/0001104659-25-107719.md) | [243](/filings/0001104659-26-090337.md) | [256](/filings/0001104659-26-058213.md) | [281](/filings/0001104659-26-090337.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [22.3 d](/filings/0001558370-24-014851.md) | [32.6 d](/filings/0001104659-26-019145.md) | [60.7](/filings/0001558370-25-006494.md) | [71.1 d](/filings/0001558370-25-009885.md) | [46.0 d](/filings/0001104659-25-107719.md) | [13.7 d](/filings/0001104659-26-019145.md) | [39.8](/filings/0001104659-26-058213.md) | [36.1 d](/filings/0001104659-26-090337.md) | [28.9 d](/filings/0001104659-25-107719.md) | [13.8 d](/filings/0001104659-26-019145.md) | [20.6](/filings/0001104659-26-058213.md) | [38.8 d](/filings/0001104659-26-090337.md) |
| Capital expenditure | $m | [0.8 d](/filings/0001558370-24-014851.md) | [1.2 d](/filings/0001104659-26-019145.md) | [1.3](/filings/0001558370-25-006494.md) | [1.4 d](/filings/0001558370-25-009885.md) | [1.6 d](/filings/0001104659-25-107719.md) | [2.1 d](/filings/0001104659-26-019145.md) | [2.6](/filings/0001104659-26-058213.md) | [2.8 d](/filings/0001104659-26-090337.md) | [2.3 d](/filings/0001104659-25-107719.md) | [1.9 d](/filings/0001104659-26-019145.md) | [2.5](/filings/0001104659-26-058213.md) | [2.4 d](/filings/0001104659-26-090337.md) |
| Dividends paid | $m | [7.5 d](/filings/0001558370-24-014851.md) | [7.5 d](/filings/0001104659-26-019145.md) | [7.6](/filings/0001558370-25-006494.md) | [7.5 d](/filings/0001558370-25-009885.md) | [7.5 d](/filings/0001104659-25-107719.md) | [7.5 d](/filings/0001104659-26-019145.md) | [7.6](/filings/0001104659-26-058213.md) | [7.7 d](/filings/0001104659-26-090337.md) | [7.7 d](/filings/0001104659-25-107719.md) | [7.8 d](/filings/0001104659-26-019145.md) | [8.0](/filings/0001104659-26-058213.md) | [8.2](/filings/0001104659-26-090337.md) |
| Share repurchases | $m | [55.9 d](/filings/0001558370-24-014851.md) | [25.9 d](/filings/0001104659-26-019145.md) | [33.0](/filings/0001558370-25-006494.md) | [48.2 d](/filings/0001558370-25-009885.md) | [35.0 d](/filings/0001104659-25-107719.md) | [24.8 d](/filings/0001104659-26-019145.md) | [5.0](/filings/0001104659-26-058213.md) | [24.9 d](/filings/0001104659-26-090337.md) | [16.4 d](/filings/0001104659-25-107719.md) | [10.0 d](/filings/0001104659-26-019145.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [156](/filings/0001558370-23-017439.md) | [156](/filings/0001558370-24-006375.md) | [157](/filings/0001558370-24-010473.md) | [158](/filings/0001558370-24-014851.md) | [155](/filings/0001558370-25-006494.md) | [156](/filings/0001558370-25-009885.md) | [153](/filings/0001104659-25-107719.md) | [155](/filings/0001104659-26-058213.md) | [156](/filings/0001104659-26-090337.md) | [161](/filings/0001104659-25-107719.md) | [162](/filings/0001104659-26-058213.md) | [166](/filings/0001104659-26-090337.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 167,117,937 at 2026-06-30, from the cover of the [10-Q filed 2026-08-04](/filings/0001104659-26-090337.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.